Open AccessOphthalmic Solution Safety Profile: Active Surveillance of a Sodium Hyaluronate/Chondroitin Sulfate Combination in Peruvian Population
Author(s) -
Homero Contreras-Salinas,
Mariana Barajas-Hernández,
Leopoldo Martín Baiza-Durán,
Vanessa Orozco-Ceja,
Lourdes Yolotzin Rodríguez-Herrera
Publication year - 2021
Publication title -
drug, healthcare and patient safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.53
H-Index - 24
ISSN - 1179-1365
DOI - 10.2147/dhps.s311817
Subject(s) - medicine , tolerability , pharmacovigilance , population , adverse effect , chondroitin sulfate , blurred vision , concomitant , chondroitin , pharmacology , surgery , anatomy , environmental health , glycosaminoglycan
Sodium hyaluronate/chondroitin sulfate fixed combination plays an essential role in the treatment of keratoconjunctivitis sicca, a multifactorial disease accompanied by ocular symptoms like alteration of the tear film. Despite low or no absorption of such drugs, these can cause secondary effects. An essential tool in the study of medication behavior is active pharmacovigilance. Unlike spontaneous reporting pharmacovigilance, this tool allows an appraisal of adverse drug reactions (ADRs)' real incidence, a higher capacity to identify safety signals, the relationship with concomitant drugs and pathologies prevalent in the study population. This study aimed to evaluate the safety profile and identify and/or assess adverse reactions in an uncontrolled population.